54.3 F
San Diego
Thursday, Mar 28, 2024
-Advertisement-

Entest BioMedical Trying to Acquire Nanotechnology

La Mesa-based Entest BioMedical Inc. announced Tuesday that the company is in discussions to acquire a nanotechnology for the delivery of cancer therapeutics in both animals and humans.

The company said the technology would potentially allow more potent therapeutics to be administered to patients than is currently possible. The reason this is possible is due to the fact that the nanoparticles sequester the drug and allow it to travel throughout the body with minimal toxicity, only releasing the drug directly to the tumor, according to a recent news release.

“Although Entest has historically focused on veterinary biotechnology, we believe that the acquisition of this nanotechnology would enable us to pursue partnering opportunities in the human market as well as the veterinary market,” said a spokesman for Entest in a statement.

Entest BioMedical (OTC PINK: ENTB) is a developer of veterinary medicines that uses the animal’s own reparative and immunological mechanisms.

-Advertisement-

Featured Articles

Oberon Eyes Europe for Renewable DME

Leaders of Influence in Law 2024

-Advertisement-
-Advertisement-

Related Articles

-Advertisement-
-Advertisement-
-Advertisement-